EUCTR2007-004760-49-GB进行中（未招募）不适用
Do Xanthine Oxidase Inhibitors reduce both Left Ventricular Hypertrophy and Vascular Dysfunction in Cardiovascular patients with Renal Dysfunction? - Allopurinol in LVH/CKD trial
niversity of Dundee0 个研究点目标入组 60 人开始时间: 2007年12月10日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with Chronic Kidney Disease Stage 3 (estimated GFR 30 - 60 ml/min/1.73m2)
- •Patients with evidence of Echo Left Ventricular Hypertrophy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Known cardiac failure
- •Patients with gout
- •Patients with severe hepatic failure
- •Patients already on Allopurinol
- •Usual contraindications to MRI including metal implants in the body and claustrophobia
- •Current immunosuppressive therapy (eg Azathioprine, Ciclosporin, Cyclophosphamide), warfarin, Chlorpropamide, Theophylline and 6 mercaptopurine
- •Malignancy or other life threatening disease
- •Pregnancy or lactating women
- •Patients who unable to give informed consent (eg learning disabilities)
研究者
相似试验
已完成
不适用
Do xanthine oxidase inhibitors reduce both left ventricular hypertrophy and endothelial dysfunction in cardiovascular patients with renal dysfunction?Chronic kidney disease (CKD) and left ventricular hypertrophy (LVH)Circulatory SystemComplications and ill-defined descriptions of heart diseaseISRCTN45773760niversity of Dundee (UK)60
已完成
不适用
Does a drug allopurinol reduce heart muscle mass and improve blood vessel function in patients with normal blood pressure and stable angina?ormotensive patients with left ventricular hypertrophy and chronic stable anginaCirculatory SystemComplications and ill-defined descriptions of heart diseaseISRCTN73579730niversity of Dundee (UK)66
进行中（未招募）
不适用
Do xanthine oxidase inhibitors reduce left ventricular hypertrophy and endothelial dysfunction in normotensive patients with chronic stable angina? - Allopurinol in normotensive patients with left ventricular hypertrophyeft ventricular hypertrophyNormotensiveChronic stable anginaMedDRA version: 9.1Level: LLTClassification code 10049773Term: Left ventricular hypertrophyMedDRA version: 9.1Level: LLTClassification code 10049194Term: Stable angina pectorisMedDRA version: 9.1Level: LLTClassification code 10005754Term: Blood pressure normalEUCTR2008-008479-32-GBniversity of Dundee66
进行中（未招募）
不适用
Do Xanthine Oxidase Inhibitors Regress Left ventricular Hypertrophy in Diabetes? - Allopurinol in LVH/DiabetesDiabetes Left Ventricular HypertrophyMedDRA version: 9.1Level: HLTClassification code 10012602Term: Diabetes mellitus (incl subtypes)MedDRA version: 9.1Level: LLTClassification code 10049773Term: Left ventricular hypertrophyEUCTR2008-008485-12-GBniversity of Dundee66
已完成
4 期
Do xanthine oxidase inhibitors regress left ventricular hypertrophy in diabetes? A whole new approach to reducing cardiac deathsISRCTN96755104niversity of Dundee (UK)66